This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Boehringer Ingelheim GmbH
Drug Names(s): BI 2536
Description: BI 2536 is a small molecule, ATP-competitive kinase inhibitor that is a derivative of dihydropteridinone. BI 2536 acts by binding to and inhibiting Polo-like kinase 1 (Plk1), resulting in mitotic arrest, disruption of cytokinesis, and apoptosis in susceptible tumor cell populations. Plk1, a serine/threonine-protein kinase, is a key regulator of multiple processes fundamental to mitosis and cell division.
BI 2536 News
Pink Sheet In Brief: PhRMA state government relations
Additional information available to subscribers only: